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ABSTRACT
Objective: To explore the effects of anti-tumour necrosis
factor (TNF)a antibody therapy on bone mineral density
(BMD) of the lumbar spine and femur neck in patients
with rheumatoid arthritis (RA).
Methods: A total of 50 patients with active RA
(DAS28>3.2) who started adalimumab (40 mg subcu-
taneously/2 weeks) were included in an open label
prospective study. All patients used stable methotrexate
and were allowed to use prednisone ((10 mg/day). The
BMD of the lumbar spine and femur neck was measured
before and 1 year after start of treatment.
Results: Disease activity at baseline (28-joint Disease
Activity Score (DAS28)) and disease duration were
inversely correlated with femoral neck BMD and lumbar
spine BMD (p,0.05). Mean BMD of lumbar spine and
femur neck remained unchanged after 1 year of
adalimumab therapy (+0.3% and +0.3%, respectively). Of
interest, a beneficial effect of prednisone on change in
femur neck BMD was observed with a relative increase
with prednisone use (+2.5%) compared to no concomi-
tant prednisone use (20.7%), (p=0.015).
Conclusion: In contrast to the progressive bone loss
observed after conventional disease-modifying antirheu-
matic drug therapy, TNF blockade may result in an arrest
of general bone loss. Consistent with previous observa-
tions, the data also suggest that the net effect of low-
dose corticosteroids on BMD in RA may be beneficial,
possibly resulting from their anti-inflammatory effects.
Osteoporosis is more frequent in patients with
rheumatoid arthritis (RA) than in the general
population due to active systemic inflammation
as well as the use of corticosteroids and immobi-
lity.
1 Osteoporosis can cause pain, loss of height
and may lead to fractures after falling. Subsequent
disability may lead to loss of independence and
quality of life. Fractures and associated comorbid-
ity may eventually even be life threatening in
elderly patients. Hence, understanding and pre-
venting osteoporosis in patients with RA is
important, especially because the age of onset of
RA is usually around the age of 50–60 and two-
thirds of patients are female and past menopause,
so already at risk of developing osteoporosis.
Tumour necrosis factor (TNF) is a key player in
the pathogenesis of RA. TNFa is not only
associated with inflammation, but also involved
in postmenopausal bone loss.
23Previous work in
animal models of RA has suggested that TNF
blockade may result in inhibition of systemic bone
loss.
4 Data describing the effect of in vivo TNFa
inhibition on general bone loss in patients with RA
are still limited and restricted to infliximab
treatment.
56 Therefore, our aim was to explore
the effects of adalimumab treatment on bone
mineral density (BMD) of the lumbar spine and
femoral neck in patients with RA in an open label,
prospective study.
Patients and methods
A total of 50 patients with active RA (28-joint
Disease Activity Score (DAS28) >3.2) who started
adalimumab treatment (40 mg subcutaneously
every other week) were included in an open label
prospective study. All patients used stable metho-
trexate (MTX) and were allowed to use prednisone
((10 mg/day) if stable at least 1 month before
inclusion. MTX was kept stable throughout the
study, prednisone dosage was allowed to be
tapered after 16 weeks of treatment and the
continuation of antiosteoporotic drugs was
allowed. Disease activity was assessed by DAS28
at week 4, 16, 28, 40 and 52. Clinical response was
defined by the European League Against
Rheumatism (EULAR) response criteria.
7
The BMD of the lumbar spine (L1–L4) and left
femoral neck was measured before treatment and
after 1 year by dual energy x ray absorptiometry
(DXA) (QDR 4500A; Hologic Inc., Waltham,
Massachusetts, USA). BMD was defined as bone
mineral content, divided by the surface of the
projected bone area, expressed in g/cm
2. T-scores
(an SD compared with the peak BMD value of an
adult aged from 20 to 30 years) and Z-scores (an
SD compared with BMD values of age and sex)
were calculated. Reference BMD values supplied by
the manufacturer were used. Osteopoenia was
defined by a T-score between 21 and 22.5 SD and
osteoporosis as a T-score below 22.5 SD, according
to the World Health Organization guidelines. The
protocol was approved by the Medical Ethics
Committee of the Academic Medical Centre,
University of Amsterdam. All patients gave writ-
ten informed consent.
Statistical analysis
Changes in BMD were analysed by paired samples
t tests. Subanalyses were performed by indepen-
dent Student t tests or Mann–Whitney U tests to
detect significant differences in baseline DXA
values and changes in BMD between groups
including differences in prednisone or antiosteo-
porotic drug use. Correlations were assessed with
the Pearson product-moment or Spearman rank-
order correlation coefficients, whichever was
appropriate. Stepwise backward multivariate linear
regression analysis was performed on the total
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vitamin D and biphosphonate), prednisone use and baseline
BMD on change in femur BMD. Values are presented as mean
(SD) or median and interquartile range (IQR). p Values ,0.05
were considered statistically significant. SPSS V. 12.0.2 for
Windows (SPSS, Chicago, Illinois, USA) was used.
RESULTS
Patients and clinical response
After 1 year of follow-up, 46 out of 50 patients completed the
whole study, while 4 patients were excluded from analysis due
to premature drop out (1 lost to follow-up, 1 infection, 1 lack of
efficacy and 1 malignancy). In one patient the BMD of the
femur neck was not performed after treatment due to hip
replacement. A total of 80% were female and the mean age 51
(14) years. The median disease duration was 60 months (IQR 36
to 142). Furthermore, 31 (67%) patients had erosive disease, 65%
was IgM-rheumatoid factor positive and 70% anti-cyclic
citrullinated peptide (CCP) positive. The mean MTX dose was
19.1 (6.9) mg/week. A total of 13 (28%) patients used
concomitant prednisone at a mean dose of 7.4 (2.3) mg/day.
Eight patients used prednisone >5.0–7.5 mg/day and five
patients used .7.5–(10.0 mg/day). Of these 13 patients, 6
received bisphosphonate therapy and 2 patients used bispho-
sphonate without prednisone. There were four patients with a
disease duration less than 1 year of whom only one used
prednisone; all other prednisone users had longstanding RA.
There were 13 patients that used calcium and vitamin D3
suppletion, of whom 9 were also treated with prednisone. In
five patients prednisone was stopped after week 16 while eight
patients still used low-dose prednisone (,10 mg/day) after 1
year. In all, 19 (51%) women were menopausal, of whom only 1
used hormonal replacement therapy, and 7 women were not
menopausal and used an oral contraceptive (see table 1 for
patient characteristics).
The mean DAS28 decreased from 5.4 (1.1) at baseline to 3.6
(1.2) at week 16 and 3.4 (0.7) at week 52 (both p,0.001). At
week 52 there were 23 good, 16 moderate and 7 non-responders
according to the EULAR response criteria.
BMD at baseline is associated with disease activity and disease
duration
Baseline mean lumbar spine BMD was 0.962 (0.150) g/cm
2 and
mean femoral neck BMD was 0.798 (0.156) g/cm
2. Only 4
(8.9%) of 46 analysed patients had osteoporosis. Osteopoenia
was found in 13 (28%) patients in femur neck and spine and in 4
patients in only the spine.
Males had a significantly higher BMD of the femoral neck
than females (p=0.011) with a similar trend for the lumbar
spine (p=0.062). There was a significant inverse correlation
between BMD and age and, as expected, disease activity at
baseline (DAS28) and disease duration were inversely correlated
with femoral neck BMD (r=20.36, p=0.015 and r=20.37,
p=0.011, respectively). Lumbar spine BMD was also inversely
correlated with the DAS28 and disease duration (r=20.44
p=0.003 and r=20.33 p=0.029, respectively). Of interest,
only BMD of the femur was correlated with body weight
(r=0.438, p=0.002). There was no difference in baseline BMD
between users and non-users of prednisone. A difference
however was found in baseline BMD of lumbar spine and
femur related to calcium, vitamin D3 or bisphosphonate use,
with lower baseline BMD values for patients using antiosteo-
porotic therapy. Naturally, their low BMD was the reason why
these patients were using antiosteoporotic drugs to begin with.
When comparing the presence or absence of erosions, rheuma-
toid factor or anti-CCP positivity we found no relationship with
pretreatment BMD.
Further decrease in BMD is arrested by adalimumab therapy
There was no significant change in mean BMD of the lumbar
spine comparing values before (0.962 (0.150) g/cm
2)v sv a l u e s
after 1 year (0.965 (0.155) g/cm
2)( +0.3%) (table 2). The mean
BMD of the femur neck also remained unchanged: 0.798
(0.156) g/cm
2 before compared to 0.800 (0.147) g/cm
2 after
1 year of adalimumab therapy (+0.3%) (see fig 1). Hence,
there was no significant increase or decrease after 1 year of
treatment.
The increase in BMD is related to the decrease in serum CRP
levels
An association was found between the decrease in serum CRP
levels at week 16 and the increase in femur neck BMD after
1 year (Pearson correlation coefficient r=20.307, p=0.040). In
addition, a possible association, just falling short of statistical
significance, was observed between the decrease in serum CRP
levels at week 52 and the increase in femur neck BMD at the
same time point (Pearson correlation coefficient r=20.292,
p=0.052).
Table 1 Baseline patient characteristics
Characteristic Total n=46
Demographics:
Age (years) 51 (14)
Female (%) 37 (80)
BMI (kg/m
2) 27.0 (5.9)
Disease status:
Disease duration (months) 60 (36 to 142)
Erosive disease (%) 31 (67)
IgM-RF+(%) 30 (65)
Anti-CCP+(%) 32 (70)
DAS28 5.4 (1.1)
ESR (mm/h) 19 (11 to 34)
CRP (mg/litre) 7 (4 to 17)
Postmenopausal women (%) 19 (51)
Drug treatments:
Previous DMARDs 4.1 (2.0)
Methotrexate (mg/week) 19.1 (6.9)
Prednisone use (%) 13 (28)
Prednisone dose (mg/day) 7.4 (2.3)
Bisphosphonate use (%) 8 (17)
Calcium use (%) 13 (28)
Vitamin D use (%) 12 (26)
Bone mineral density:
Lumbar spine
BMD (g/cm
2) 0.96 (0.15)
T-score (SD) 20.82 (1.32)
Z-score (SD) 0.04 (1.23)
Femoral neck
BMD (g/cm
2) 0.80 (0.16)
T-score (SD) 20.75 (1.32)
Z-score (SD) 0.19 (1.19)
Mean values (SD), median and interquartile range (IQR) or percentages are shown.
BMD, bone mineral density; BMI, body mass index; CCP, cyclic citrullinated peptide;
CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARD, disease-
modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; RF, rheumatoid
factor.
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Interestingly, univariate analysis indicated that the concomi-
tant use of prednisone, calcium and vitamin D3 was associated
with a greater increase in femur BMD compared to patients
who did not use these drugs in combination with adalimumab.
Especially, mean femur BMD showed a relative increase when
prednisone was used: before 0.758 (0.117) vs after 1 year 0.777
(0.122) (+2.5%) compared to no concomitant prednisone use
0.814 (0.167) vs 0.808 (0.126) (20.7%), (p=0.015, see fig 1). A
trend was observed for changes in lumbar spine BMD
(p=0.072). Although this was statistically significant for all
three drugs, this exploratory study was not formally powered to
study significant differences in mean change between groups. In
response to this interesting observation, we performed stepwise
backward multivariate linear regression analysis to study how
much of the change in femur BMD independent of the overall
effect of adalimumab could be explained by the use of these
drugs. Interaction between prednisone, bisphosphonate, cal-
cium and vitamin D use was studied by using an interaction
variable in the analysis. We found that the pretreatment femur
neck BMD (p=0.035) and the use of prednisone (p=0.031)
together explained 18.5% (adjusted R
2) of the variance in BMD
change.
Only the use of vitamin D3 showed an interaction with
prednisone use. However, by including baseline femur BMD in
the model vitamin D was rejected, because vitamin D was
associated with a lower mean femur BMD pretreatment
(vitamin D3 use 0.659 (0.104) vs no vitamin D3 use 0.847
(0.141), p,0.001), while prednisone use was unrelated to
baseline femur BMD. Hence, these data suggest that in addition
to the overall effect of adalimumab in all patients, 18.5% of the
change in BMD of the femur is explained by baseline BMD and
prednisone use.
DISCUSSION
The results of this study confirm and extend previous findings
with infliximab in RA. We observed that BMD does not increase
significantly after 1 year of adalimumab therapy, but on average
progressive bone loss is halted.
Several studies have been performed with infliximab to study
the effect of TNFa blockade on general bone loss in RA and
ankylosing spondylitis.
5 8–10 The results vary by study with
regard to the magnitude of observed change, but also with
regard to the time points of DXA scanning, the numbers of
patients included and the concomitant use of prednisone and/or
antiosteoporotic drugs. Our results are consistent with the
findings of two previous studies on the effects of infliximab
where bone mineral density was measured after 1 year and
concomitant use of steroids and bisphosphonate was also
allowed. The results from both studies suggest an arrest in
further bone loss after TNF blockade.
59However, one of the
latter studies showed that bone loss of the hands as measured
by radiogrammetry was ongoing despite TNF blockade.
5
The limitation of our study and previous studies is the fact
that the design is not double blind and placebo controlled,
making it difficult to interpret the size of the effect of TNF
blockade. Because observed changes in BMD are very small in
most bone mineral density studies and the SD of BMD
measurements is quite large, a simple power calculation would
tell us that one would need a study including around at least
500 patients to detect a significant change in BMD that is
greater than the variance in BMD within the study group.
However, a recent study used an elegant alternative by
describing the change in BMD of femur and lumbar spine in a
control group of 99 patients with RA using no TNF blocker but
only methotrexate.
9 The disease duration was comparable to
the study group comprising 90 patients using infliximab in
combination with methotrexate. Similar to our study, con-
comitant use of prednisone and bisphosphonates was allowed,
resembling the normal RA population seen in the everyday
rheumatology practice. Their results showed that within 1 year
of follow-up the BMD of lumbar spine as well as the femur
BMD decreased in the control group (23.9% and 22.5%,
respectively) while mean lumbar spine and femur BMD
remained unchanged in 90 patients using infliximab in
Figure 1 Change in femur neck bone mineral density (BMD) after
1 year of adalimumab therapy. Data are represented as mean (symbol)
and SD (whiskers). After 1 year (T=1) of adalimumab therapy the mean
femur neck BMD was unchanged (+0.3%) (n=46, circle). However, the
concomitant use of prednisone led to a relative increase in mean femur
neck BMD (+2.5%) (n=13, square) compared to patients who did not
use prednisone (20.7%) (n=33, diamond).
Table 2 Femur neck and lumbar spine bone mineral density (BMD) before and after 1 year
BMD T=0 BMD T=1 year
p Value Median (IQR) Mean (SD) Median (IQR) Mean (SD)
Femur
neck
0.795 (0.703 to 0.920) 0.798 (0.156) 0.798 (0.685 to 0.901) 0.800 (0.147) NS
Lumbar
spine
0.961 (0.850 to 1.070) 0.962 (0.150) 0.963 (0.845 to 1.070) 0.965 (0.155) NS
BMD, bone mineral density; IQR, interquartile range; NS, not significant.
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population study with patients with RA on traditional
DMARD therapy (48% using corticosteroids and 37% using
antiresorptive drugs) showed mean bone loss of the spine to be
around 20.29% and of the femur neck around 20.64% after
1 year. In patients not using antiresorptive therapy but calcium
and vitamin D alone bone loss of the spine was around 21.99%
and 21.39% of the femur neck after 1 year.
1 In early arthritis
patients the percentage of bone loss is even higher (22.4% in
the spine and 24.3% in the trochanter after 1 year).
11 With this
perspective the results observed after anti-TNFa therapy
suggest a favourable effect on generalised BMD.
This brings up the unexpected observation in our study of a
potentially beneficial effect of prednisone on BMD change of
the femur neck, for prednisone use is obviously more often
associated with loss of bone mineral density. Corticosteroid use
has been shown to be an independent risk factor for vertebral
fractures.
12 Recently however a placebo controlled trial found a
positive effect of prednisone on hand bone density compared to
placebo in early RA.
13 Hence, prednisone can have a negative
effect on bone mineral density when chronically used in high
dose, but the beneficial effect of prednisone on further
dampening inflammation and associated bone loss cannot be
discarded. In addition, clinical improvement due to prednisone
use and increased mobility due to clinical improvement may
also have contributed to a positive effect on bone mineral
density. The actual size of the potentially beneficial effect
should further be determined in a placebo controlled study to
rule out the impact of, for instance, regression to the mean,
which might have exerted some influence in our cohort study,
because baseline femur neck BMD was slightly lower in
prednisone users. Of interest, in a recent study the effect of
infliximab on femur BMD was no longer significant when
steroid use was added to the multivariate model in addition to
male sex and age.
9 Although only an interaction between
vitamin D suppletion and prednisone was identified by multi-
variate linear regression analysis, it cannot be completely ruled
out that antiosteoporotic treatment in a subset of these patients
added to the relative increase in bone mineral density of the
femur neck. In summary this is the first study to show
progressive general bone loss may also be arrested by
adalimumab therapy. The data also suggest that the net effect
of low-dose corticosteroids on BMD in RA may be beneficial,
which may be explained by the anti-inflammatory effects.
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